A

ease type a plus sign (+) inside this box \longrightarrow

Signature

PTO/SB/05 (03-01)
Approved for use through10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

December 14, 2001

Date

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. NOV 1000 CON1 Attorney Docket No. UTILITY PATENT APPLICATION Gilles Gosselin First Inventor TRANSMITTAL Express Mail Label No. EK566763090US (Only for new nonprovisional applications under 37 CFR 1 53(b)) β-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B Title ADDRESS TO: Assistant Commissioner of Patents **Application Elements Box Patent Application** Washington, D.C. 20231 See MPEP chapter 600 concerning utility patent application contents CD-ROM or CD-R in duplicate, large table or Fee Transmittal Form (Submit an original, and a duplicate for fee processing) Computer Program (Appendix) Nucleotide and/or Amino Acid Sequence Submission Applicant claims small entity status. (if applicable, all necessary) See 37 CFR 1.27 Computer Readable Form (CRF) Specification Sequence Listing on: [Total Pages Specification CD-ROM or CD-R (2 copies); or (preferred arrangement set forth below) paper Descriptive title of the invention Statement verifying identity of above copies Cross Reference to Related Applications Statement Regarding Fed sponsored R & D ACCOMPANYING APPLICATION PARTS Reference to sequence listing, a table, or a computer program listing appendix Assignment Papers (cover sheet & document(s)) Background of the Invention 37 CFR 3.73(b) Statement Brief Summary of the Invention (when there is an assignee) Brief Description of the Drawings (if filed) Detailed Description ☐ Power of Attorney Claim(s) 11. English Translation Document (if applicable) Abstract of the Disclosure 12. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations [Total Pages Drawing(s) (35 U S.C. 113) Preliminary Amendment 14. X Return Receipt Postcard (MPEP 503) Oath or Declaration [Total Pages (Should be specifically itemized) Newly executed (original or copy) Certified Copy of Priority Document(s) Copy from prior application (37 CFR 1.63(d)) (if foreign priority is claimed) (for continuation/divisional with Box 17 completed) Nonpublication Request under 35 U.S.C. 122 16. **DELETION OF INVENTOR(S)** (b)(2)(B)(i). Applicant must attach form Signed statement attached deleting inventor(s) named in PTO/SB/35 or its equivalent. the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 17. Other: Certificate of Express Mailing Application Data Sheet. See 37 CFR 1.76 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: of prior application No: 09 / 371,747 Divisional Continuation-in-part (CIP) Group/Art Unit: 1623 Prior application information: Examiner: L. Eric Crane For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS (Insert Customer, No. of Artach bar code label here) or Correspondence address below Customer Number or Bar Code Label Firm or Sherry M. Knowles, Esq. (Registration No. 33,052) and Josephine Young (Registration No. 48,308) Individual Name Address King & Spalding 191 Peachtree Street ZIP 30303-1763 City Atlanta State GA 404-572-5145 Telephone 404-572-3541 Country U.S.A. 33,052 Registration No. (Attorney/Agent) Name (Print Type): Sherry M. Knowles, Esq

FEE TRANSMITTAL

This sheet accompanies a patent application transmittal for the following application:

Inventor(s): Gilles Gosselin et al. Filing Date: December 14, 2001 Title: β-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B							
The filing fee is calculated as shown below: 1. FILING FEE: COMMAN DESCRIPTION							
				SMALL ENTITY		LARGE ENTITY	
FOR:				FEE	FEE PAID	FEE	FEE PAID
UTILITY FILING FEE				\$370.00		\$740.00	\$740.00
DESIGN FILING FEE				\$165.00		\$330.00	<u> </u>
PLANT FILING FEE				\$255.00		\$510.00	
REISSUE FILING FEE				\$370.00		\$740.00	
PROVISIONAL FILING FEE				\$80.00		\$160.00	
SUBTOTAL (1) \$74							
SUBTOTAL (1) 2. CLAIMS: SMALL ENTITY LARGE ENTITY FOR: NO. FILED NO. EXTRA RATE FEE RATE							
u 2. od U				SMALL ENTITY		LARGE ENTITY	
F	OR:	NO. FILED	NO. EXTRA	RATE	FEE	RATE	FEE
TOTAL CLAIMS		73 - 20 =	53	x \$9 =		x \$18 =	\$954.00
TOTAL CLAIMS INDEP. CLAIMS		27 - 3 =	24	x \$42 =		x \$84 =	\$2,016.00
MULTIPLE DEPENDENT CLAIM PRESENTED				+\$140 =		+\$280 =	\$280.00
: #	•		SUI	BTOTAL (2)			\$3,250.00
± 3. ADDITIONAL FEES:							
SMALL ENTITY LARGE ENTITY							
3. ADDITIONAL FEES: FOR:				FEE	FEE PAID	FEE	FEE PAID
FOR: LATE FILING, FEE OR OATH				\$65	FEETAID	\$130	TEETAID
NON-ENGLISH SPECIFICATION				\$130		\$130	
	OTHER					-	
SUBTOTAL (3)							
TOTAL FILING FEES: \$ 3,990.00							
A check is enclosed for the amount: \$ 3,990.00							
Charge any additional fees required under 37 C.F.R. 1.16 or 1.17 to Deposit Account 11-0980.							
KING & SPALDING 45 th Floor, 191 Peachtree Street, N.E.							
Atlanta, Georgia 30303							
Telephone: 404.572.4600							
By: Sherry M luwles Date: December 14, 2001							
Sherry M. Knowles, Attorney for Applicant							
Reg. No. 33,052							

CERTIFICATE OF MAILING UNDER 37 CFR § 1.10 FOR UTILITY PATENT APPLICATION FILING

I hereby certify that this Request for filing a Continuation Application, Transmittal of Utility Patent Application, Utility Patent Application, Preliminary Amendment, and Fee Transmittal, along with any documents referred to as attached therein are being deposited with the United States Postal Service in an envelope as "Express Mail Post Office to Addresses" services under 37 CFR 1.10, Mailing Label Number <u>EK566763090US</u> addressed to Box PATENT APPLICATION; Commissioner for Patents; Washington, DC 20231.

Josephine Young

Reg. No. 48,308

Date: **December 14, 2001**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Gosselin et al.

Filed:

Herewith

Serial No.:

Unassigned

Continuation of U.S.S.N. 09/371,747

.11. 09/3/1,/4/

Group Art Unit: 1623

Filed: August 10, 1999

Examiner: L. Eric Crane

For:

β-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B

Box Patent Application Assistant Commissioner for Patents Washington, DC 20231

December 14, 2001

REQUEST FOR FILING A CONTINUATION APPLICATION UNDER 37 CFR § 1.53(b)

Sir:

This is a request by Gilles Gosselin, Jean-Louis Imbach and Martin L. Bryant for filing a Continuation Application under 37 C.F.R. § 1.53(b) of pending prior application U.S. Serial No. 09/371,747, filed on August 8, 1999, now allowed.

Enclosed is a copy of the prior application U.S.S.N. 09/371,747 as originally filed on August 8, 1999. The application includes fifty-one pages of Specification, five pages of Claims, one page of Abstract, and four sheets of Formal Drawings. I hereby verify that the attached papers are a true copy of what is shown in my records to be the above-identified prior application.

Gilles Gosselin, Jean-Louis Imbach and Martin L. Bryant have assigned their interest in the application to Novirio Pharmaceuticals Limited and the Centre National da la Reserche Scientifique in an assignment recorded on September 27, 1999, at Reel 010271, Frame 0725. A copy of the recorded assignment is enclosed. Also enclosed are copies of the executed Declarations for Patent Application and Powers of Attorney.

REQUEST FOR CONTINUATION APPLICATION of U.S.S.N. 08/161,674
Filed August 10, 1999

A Preliminary Amendment is enclosed. Applicants request entry of the Preliminary Amendment prior to fee calculation. Pursuant to the telephone conversation with the Examiner, the claims of the continuation application closely parallel those allowed in the parent application.

Applicants enclose a check for \$3,990.00 to cover the filing fee. The Assistant Commissioner for Patents is authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 11-0980.

Respectfully submitted,

Sherry M. Knowles

Reg. No. 33,052

Date: December 14, 2001

Express Mail Label No. EK566763090US

King & Spalding 191 Peachtree Street Atlanta, Georgia 30303 404-572-3541 (telephone) 404-572-5145 (facsimile)

Attorney Docket No. 06171.105005 (NOV 1000 CON1)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Gosselin et al.

Filed:

Herewith

Serial No.:

Unassigned

Continuation of U.S.S.N. 09/371,747

J.B.B.IV. 07/3/1,/4/

Group Art Unit: 1623

Filed:

August 10, 1999

Examiner: L. Eric Crane

For:

β-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B

Box Patent Application Assistant Commissioner for Patents Washington, DC 20231

December 14, 2001

REQUEST FOR NON-PUBLICATION AND CERTIFICATION UNDER 35 U.S.C. § 122(b)(2)(B)(i)

Sir:

I hereby certify that the invention disclosed in the above-identified application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the above-identified application not be published under 35 U.S.C. § 122(b). The above-identified application is being filed on the same date as this Request for Non-Publication.

Respectfully submitted,

Sherry M. Knowles, Esq.

Reg. No. 33,052

King & Spalding 191 Peachtree Street Atlanta, Georgia 30303 Telephone: 404-572-3541 Facsimile: 404-572-5145